Navigation Links
Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
Date:4/6/2009

COSTA MESA, Calif., April 6 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) announced today that company Chairman and CEO, Chris Stern, has posted a new entry on his blog on the company website. The latest blog discusses the company's recent meetings in Zurich, Switzerland, further development plans for Oxycyte(R) in indications beyond traumatic brain injury, supply plans for clinical-grade Oxycyte, and plans for raising additional capital.

The blog is available on the company's Electronic Shareholder Forum which can be found via the Investor Relations page of the company website at www.oxybiomed.com.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The Company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis pain, trauma, wound care, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, and diabetes.


'/>"/>
SOURCE Oxygen Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
2. Oxygen Biotherapeutics, Inc. Adds Oxycyte TBI Clinical Trial Sites in Israel
3. Oxygen Biotherapeutics, Inc. Expands Board of Directors
4. Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment
5. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
6. Finesse Introduces TruFluor(TM) DO, a Single-Use Optical Dissolved Oxygen Sensor and Transmitter
7. Senexis and O2H (Oxygen Healthcare) Announce Medicinal Chemistry Collaboration
8. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
9. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
10. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
11. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... DALLAS , July 29, 2014 ... Market Slide Scanners (Whole Slide Imaging), Analytics (Image Analysis Software), ... Storage - Global Forecasts & Trends to 2018", published ... and restraints in geographies such as North ... Asia , and the Rest of the ...
(Date:7/29/2014)... 29, 2014 /PRNewswire-iReach/ -- Nanosyn, Inc. announced today ... Inc., to provide access to Nanosyn,s microfluidics screening ... platform for novel small molecule therapeutics. ... to work with FORMA Therapeutics to explore key ... homeostasis. FORMA Therapeutics, decision to work with us ...
(Date:7/29/2014)... 2014  Cannabis Science, Inc. (OTC: CBIS), a ... and related consulting, applauds the Editorial Board of ... position in opposition to current federal law on ... The New York Times also announces a series ... the issue called "High Time:  An Editorial Series ...
(Date:7/29/2014)... Denver, CO (PRWEB) July 29, 2014 ... and soiled linen collection and transport solutions for hospitals, ... Society for Healthcare Engineering (ASHE) Annual Conference & Technical ... TransVac will present its technology for making hospitals cleaner, ... operational costs over the hospital’s life cycle. Staff ...
Breaking Biology Technology:Digital Pathology Market worth $437 Million by 2018 2Digital Pathology Market worth $437 Million by 2018 3Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2
... , PHILADELPHIA, July 13 ERT (Nasdaq: ... technology, and other services to the biopharmaceutical, medical device, and related ... 2009 second quarter on Thursday, July 30, 2009 after the market ... at 5:00 PM EDT that day. , , ...
... , SAN JOSE, Calif., July ... of measurement and control solutions for biologics applications today announced ... BIIB ) aimed at evaluating emerging technologies for single-use bioprocessing. ... control algorithms. , , ...
... LEXINGTON, Mass. and HEIDELBERG, Germany, July 13 ... first human cancer biochip for HybSelect, febit,s highly automated technology for ... biochip features 115 important genes which are reported to be associated ... , , "Molecular signatures defined ...
Cached Biology Technology:ERT to Announce 2009 Second Quarter Results on July 30, 2009 2Finesse Solutions Forges Agreement With Leading Biotechnology Company for Single-Use Technology Exploration 2First Catalog Cancer Biochip for Sequence Capture Now Available from febit 2
(Date:7/28/2014)... additional coral communities showing signs of damage from the Deepwater ... spill in the Gulf of Mexico. The discovery was made ... at Penn State University. A paper describing this work and ... of Mexico will be published during the last week of ... Proceedings of the National Academy of Sciences . , ...
(Date:7/28/2014)... -- Fifteen years ago, MIT professor John Essigmann and colleagues ... an HIV drug. They thought if they could induce the ... and eventually die out a strategy that our immune ... such a drug, which caused HIV to mutate at an ... virus from patients in a small clinical trial reported in ...
(Date:7/28/2014)... other forms of dementia, but the research community is ... Washington bioengineers have a designed a peptide structure that ... proteins into a state that,s linked to widespread diseases ... and Lou Gehrig,s disease. The synthetic molecule blocks these ... an abnormally folded form by targeting a toxic intermediate ...
Breaking Biology News(10 mins):Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3
... Institute Associate Professor Marisa Roberto has been awarded the ... the Ordine al Merito della Repubblica Italiana (Order of ... addictive behavior. Traditionally bestowed by the president ... "merit acquired by the nation" in literature, the arts, ...
... been told you,re going on a trip. The only problem ... traveling, or what you,ll do when you get there. ... is on right now. As land use, human population, consumption ... with complex and unpredictable interactions, it,s anybody,s guess where we,ll ...
... recent book chapter about sugar-based chemicals is topping ... list. "Sugar-Based Chemicals for Environmentally Sustainable Applications" ... http://pubs.acs.org/doi/abs/10.1021/bk-2010-1061.ch001 and is racking up kudos. ... and research professors A. J. East and W. ...
Cached Biology News:U of M researchers find smart decisions for changing environmental times 2Sugar-based chemicals book chapter by NJIT professor takes ACS kudos 2
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
Each 72-well MiniTray is low profile, with lid. Conical well shape, 10 l....
The E. coli Expression System with Gateway Technology is designed to create E. coli expression clones containing the T7 promoter. The expression clones are ready for transformation and expression in ...
...
Biology Products: